AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Taysha Gene Therapies, Inc. Common Stock
XNAS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG00TJXFDQ0
3.96▼ 0.04 (-1.12%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
4.01
Day's Range
3.76 – 3.98
52-Week Range
3.46 – 7.30
Volume
2.5M
Avg Volume
4.0M
Share Statistics
Shares Outstanding
Employees
99
Exchange
XNAS
Listed
2020-09-24
Share count as of August 11, 2026

Taysha Gene Therapies, Inc. Common Stock (TSHA) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Taysha Gene Therapies, Inc. Common Stock (TSHA)
What is Taysha Gene Therapies, Inc. Common Stock's Market Cap?
Taysha Gene Therapies, Inc. Common Stock's Market Cap is $1.3B, based on as-reported figures from SEC (XBRL) filings.
What is Taysha Gene Therapies, Inc. Common Stock's Enterprise Value?
Taysha Gene Therapies, Inc. Common Stock's Enterprise Value is $884.3M, based on as-reported figures from SEC (XBRL) filings.
What is Taysha Gene Therapies, Inc. Common Stock's Price / Sales?
Taysha Gene Therapies, Inc. Common Stock's Price / Sales is 235.2×, based on as-reported figures from SEC (XBRL) filings.
What is Taysha Gene Therapies, Inc. Common Stock's EV / Revenue?
Taysha Gene Therapies, Inc. Common Stock's EV / Revenue is 161.2×, based on as-reported figures from SEC (XBRL) filings.
What is Taysha Gene Therapies, Inc. Common Stock's EV / EBITDA?
Taysha Gene Therapies, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Taysha Gene Therapies, Inc. Common Stock's Revenue (TTM)?
Taysha Gene Therapies, Inc. Common Stock's Revenue (TTM) is $5.5M, based on as-reported figures from SEC (XBRL) filings.
What is Taysha Gene Therapies, Inc. Common Stock's Net Income (TTM)?
Taysha Gene Therapies, Inc. Common Stock's Net Income (TTM) is -$149.6M, based on as-reported figures from SEC (XBRL) filings.
What is Taysha Gene Therapies, Inc. Common Stock's EBITDA?
Taysha Gene Therapies, Inc. Common Stock's EBITDA is -$152.0M, based on as-reported figures from SEC (XBRL) filings.
What is Taysha Gene Therapies, Inc. Common Stock's Diluted EPS (TTM)?
Taysha Gene Therapies, Inc. Common Stock's Diluted EPS (TTM) is -0.46, based on as-reported figures from SEC (XBRL) filings.
What is Taysha Gene Therapies, Inc. Common Stock's EBITDA Margin?
Taysha Gene Therapies, Inc. Common Stock's EBITDA Margin is -2771.0%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · TSHAAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue
YoY growth-100.0%-100.0%+171.3%-100.0%
Operating expenses:
Research and development
General and administrative
Net gain on lease termination———
Total operating expenses
% of revenue——616.0%—
Loss from operations
% of revenue——-516.0%—
Other income (expense):
Change in fair value of warrant liability
Change in fair value of term loan
Interest income
Interest expense
Other expense
Total other income (expense), net
Net loss
% of revenue——-507.8%—
Net loss per common share, basic
Net loss per common share, diluted